The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.
- Author:
Hee Jae JUNG
1
;
Young Seok KIM
;
Sang Gyune KIM
;
Yun Nah LEE
;
Soung Won JEONG
;
Jae Young JANG
;
Sae Hwan LEE
;
Hong Soo KIM
;
Boo Sung KIM
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: Lipid metabolism; Insulin resistance; Chronic hepatitis C
- MeSH: Adult; Aged; Antiviral Agents/pharmacology/*therapeutic use; Cholesterol/blood; Drug Therapy, Combination; Female; Genotype; Hepacivirus/genetics; Hepatitis C, Chronic/*drug therapy; Humans; *Insulin Resistance; Interferon-alpha/pharmacology/*therapeutic use; Lipid Metabolism/drug effects; Male; Middle Aged; Polyethylene Glycols/pharmacology/*therapeutic use; Recombinant Proteins/pharmacology/therapeutic use; Ribavirin/*therapeutic use; Treatment Outcome; Triglycerides/blood
- From:Clinical and Molecular Hepatology 2014;20(1):38-46
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was to determine the association between CHC treatment response and lipid profile and IR change during treatment. METHODS: In total, 203 CHC patients were reviewed retrospectively between January 2005 and December 2011 at Soon Chun Hyang University Hospital. The lipid profile, homeostasis model for assessment (HOMA) of IR (HOMA-IR), and HOMA of beta cells (HOMA-beta) were evaluated before interferon plus ribavirin therapy (BTx), at the end of treatment (DTx), and 24 weeks after the end of treatment (ATx). RESULTS: A sustained virologic response (SVR) was achieved by 81% of all patients (49/60), 60% (n=36) of whom possessed genotype 1, with the remainder being non-genotype-1 (40%, n=24). Apart from age, which was significantly higher in the non-SVR group (SVR, 48.0+/-11.2 years, mean+/-SD; non-SVR, 56.6+/-9.9 years; P<0.01), there were no significant differences in the baseline characteristics between the SVR and non-SVR groups. In the SVR group, low density lipoprotein-cholesterol (LDL-C) had significantly changed at DTx and ATx compared to BTx. In addition, HOMA-IR and HOMA-beta were significantly changed at DTx in the SVR group. Among those with a high baseline insulin resistance (HOMA-IR >2.5), HOMA-IR was significantly changed at DTx in the SVR group. CONCLUSIONS: LDL-C appears to be associated with HCV treatment in SVR patients. Furthermore, eradication of HCV may improve whole-body IR and insulin hypersecretion, as well as high baseline insulin resistance (HOMA-IR >2.5).
